Prescriptions for glucagon-like peptide-1 (GLP-1) receptor agonists among adolescents and young adults in the United States increased 594% between 2020 and 2023, according to a research letter published in the Journal of the American Medical Association (JAMA). This surge reflects a broader shift in clinical practice regarding the management of pediatric obesity and type 2 diabetes.
The Scale of GLP-1 Usage in Adolescents
Data analyzed by researchers from the University of Michigan and other institutions indicate that the monthly number of individuals aged 12 to 25 prescribed GLP-1 medications—such as semaglutide and liraglutide—rose from approximately 8,700 in 2020 to more than 60,000 by the end of 2023. This analysis, which utilized data from a large national pharmacy database, highlights a rapid adoption rate following the expansion of clinical indications for these medications.
Why Are Prescriptions Increasing?
The rise in usage corresponds with significant regulatory milestones and clinical guidelines. In 2020, the U.S. Food and Drug Administration (FDA) approved liraglutide for weight management in adolescents aged 12 and older. This was followed by the 2022 approval of semaglutide for the same demographic.
According to the American Academy of Pediatrics (AAP) 2023 clinical practice guidelines, clinicians should offer adolescents with obesity access to metabolic and bariatric surgery and pharmacotherapy as adjuncts to comprehensive lifestyle interventions. The AAP emphasizes that these treatments are evidence-based tools for managing the health risks associated with pediatric obesity, which affects approximately one in five children and adolescents in the U.S.
Clinical Considerations and Safety
While the increase in prescribing is significant, medical experts emphasize that GLP-1 agonists are not intended as a standalone solution. These medications work by mimicking hormones that regulate appetite and blood sugar, but they are most effective when paired with nutritional counseling and physical activity programs.
The FDA has noted that common side effects for these medications include gastrointestinal issues such as nausea, vomiting, and diarrhea. Because the long-term effects of these drugs on a developing adolescent body are still being studied, clinical practice often involves close monitoring by pediatric endocrinologists and weight management specialists to track growth, nutritional status, and potential side effects.
Comparison of Clinical Perspectives
The rapid uptake of GLP-1 medications has sparked discussion regarding the balance between clinical need and potential over-prescribing.
| Feature | Clinical Context |
|---|---|
| Primary Indication | Type 2 diabetes and chronic weight management. |
| AAP Stance | Supports pharmacotherapy as an evidence-based tool for obesity. |
| Risk Factors | Potential for GI side effects; long-term developmental impact unknown. |
| Growth Trend | 594% increase in patients aged 12–25 (2020–2023). |
While some observers point to the potential for misuse or reliance on medications for cosmetic weight loss, the data from the JAMA report focuses on the clinical population seeking treatment for diagnosed conditions. As insurance coverage continues to evolve, the medical community remains focused on ensuring that these therapies are prescribed to patients who meet strict diagnostic criteria and are supported by a multidisciplinary care team.